Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer
MetadataShow full item record
AuthorMartín Blázquez, Ariadna; Díaz, Caridad; González Flores, Encarnación; Franco Rivas, Daniel; Jiménez Luna, Cristina; Melguizo Alonso, Consolación; Prados, José; Genilloud Rodríguez, Olga; Vicente, Francisca; Caba, Octavio; Pérez del Palacio, José
Martín-Blázquez, A., Díaz, C., González-Flores, E., Franco-Rivas, D., Jiménez-Luna, C., Melguizo, C., ... & del Palacio, J. P. (2019). Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Scientific Reports, 9(1), 1-9.
SponsorshipThis study was supported by a grant (n° 15CC056/DTS17/00081- ISCIII-FEDER) from the Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO) and Roche Pharma S.L. Authors from the Fundación MEDINA acknowledge the receipt of financial support from this public-private partnership of Merck Sharp & Dohme de España S.A. with the University of Granada and Andalusian Regional Government (PIN-0474-2016).
Colorectal cancer is one of the main causes of cancer death worldwide, and novel biomarkers are urgently needed for its early diagnosis and treatment. The utilization of metabolomics to identify and quantify metabolites in body fluids may allow the detection of changes in their concentrations that could serve as diagnostic markers for colorectal cancer and may also represent new therapeutic targets. Metabolomics generates a pathophysiological ‘fingerprint’ that is unique to each individual. The purpose of our study was to identify a differential metabolomic signature for metastatic colorectal cancer. Serum samples from 60 healthy controls and 65 patients with metastatic colorectal cancer were studied by liquid chromatography coupled to high-resolution mass spectrometry in an untargeted metabolomic approach. Multivariate analysis revealed a separation between patients with metastatic colorectal cancer and healthy controls, who significantly differed in serum concentrations of one endocannabinoid, two glycerophospholipids, and two sphingolipids. These findings demonstrate that metabolomics using liquid-chromatography coupled to high-resolution mass spectrometry offers a potent diagnostic tool for metastatic colorectal cancer.